RU2008138266A - Составы для парентерального введения лекарств и их применения - Google Patents
Составы для парентерального введения лекарств и их применения Download PDFInfo
- Publication number
- RU2008138266A RU2008138266A RU2008138266/15A RU2008138266A RU2008138266A RU 2008138266 A RU2008138266 A RU 2008138266A RU 2008138266/15 A RU2008138266/15 A RU 2008138266/15A RU 2008138266 A RU2008138266 A RU 2008138266A RU 2008138266 A RU2008138266 A RU 2008138266A
- Authority
- RU
- Russia
- Prior art keywords
- concentration
- composition according
- composition
- calcium
- salt
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 22
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 238000007911 parenteral administration Methods 0.000 title 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract 10
- IFGIYSGOEZJNBE-LHJYHSJWSA-N (3s,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one;bromide Chemical group [Br-].C([N@@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 IFGIYSGOEZJNBE-LHJYHSJWSA-N 0.000 claims abstract 9
- 229960002834 methylnaltrexone bromide Drugs 0.000 claims abstract 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract 8
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical group Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 claims abstract 7
- 229960001269 glycine hydrochloride Drugs 0.000 claims abstract 7
- 239000000243 solution Substances 0.000 claims abstract 7
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 claims abstract 6
- JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 claims abstract 4
- 239000004471 Glycine Substances 0.000 claims abstract 4
- 239000007864 aqueous solution Substances 0.000 claims abstract 4
- 159000000007 calcium salts Chemical class 0.000 claims abstract 4
- 239000002738 chelating agent Substances 0.000 claims abstract 4
- 229960002449 glycine Drugs 0.000 claims abstract 4
- 239000007951 isotonicity adjuster Substances 0.000 claims abstract 4
- 229960002921 methylnaltrexone Drugs 0.000 claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 239000011780 sodium chloride Substances 0.000 claims abstract 4
- 239000003381 stabilizer Substances 0.000 claims abstract 4
- RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical group [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
Abstract
1. Фармацевтическая композиция, содержащая эффективное количество метилналтрексона или его фармацевтически приемлемой соли, кальциевую соль хелатирующего агента, изотонический агент и стабилизатор на основе глицина в водном растворе, причем рН указанного раствора составляет от примерно 2,5 до примерно 6. ! 2. Композиция по п.1, отличающаяся тем, что указанный метилналтрексон представляет собой бромид метилналтрексона. ! 3. Композиция по п.2, отличающаяся тем, что концентрация указанного бромида метилналтрексона составляет 20 мг/мл. ! 4. Композиция по п.2, отличающаяся тем, что указанная кальциевая соль хелатирующего агента представляет собой кальциево-динатриевую соль этилендиаминтетрауксусной кислоты (ЭДТА). ! 5. Композиция по п.2, отличающаяся тем, что указанный изотонический агент представляет собой хлорид натрия. ! 6. Композиция по п.2, отличающаяся тем, что указанный стабилизатор на основе глицина представляет собой гидрохлорид глицина. ! 7. Композиция по п.2, отличающаяся тем, что рН указанного раствора составляет примерно 3,5. ! 8. Фармацевтическая композиция, содержащая бромид метилналтрексона, кальциево-натриевую соль этилендиаминтетрауксусной кислоты (ЭДТА), хлорид натрия и гидрохлорид глицина в водном растворе, причем рН указанного раствора составляет от 2,5 до 6. ! 9. Композиция по п.8, отличающаяся тем, что концентрация указанного бромида метилналтрексона составляет 20 мг/мл. ! 10. Композиция по п.8, отличающаяся тем, что концентрация указанной кальциево-натриевой соли этилендиаминтетрауксусной кислоты (ЭДТА) составляет от примерно 0,1 до примерно 1,0 мг/мл. ! 11. Композиция по п.10, отличающаяся тем, что концентрация указан
Claims (14)
1. Фармацевтическая композиция, содержащая эффективное количество метилналтрексона или его фармацевтически приемлемой соли, кальциевую соль хелатирующего агента, изотонический агент и стабилизатор на основе глицина в водном растворе, причем рН указанного раствора составляет от примерно 2,5 до примерно 6.
2. Композиция по п.1, отличающаяся тем, что указанный метилналтрексон представляет собой бромид метилналтрексона.
3. Композиция по п.2, отличающаяся тем, что концентрация указанного бромида метилналтрексона составляет 20 мг/мл.
4. Композиция по п.2, отличающаяся тем, что указанная кальциевая соль хелатирующего агента представляет собой кальциево-динатриевую соль этилендиаминтетрауксусной кислоты (ЭДТА).
5. Композиция по п.2, отличающаяся тем, что указанный изотонический агент представляет собой хлорид натрия.
6. Композиция по п.2, отличающаяся тем, что указанный стабилизатор на основе глицина представляет собой гидрохлорид глицина.
7. Композиция по п.2, отличающаяся тем, что рН указанного раствора составляет примерно 3,5.
8. Фармацевтическая композиция, содержащая бромид метилналтрексона, кальциево-натриевую соль этилендиаминтетрауксусной кислоты (ЭДТА), хлорид натрия и гидрохлорид глицина в водном растворе, причем рН указанного раствора составляет от 2,5 до 6.
9. Композиция по п.8, отличающаяся тем, что концентрация указанного бромида метилналтрексона составляет 20 мг/мл.
10. Композиция по п.8, отличающаяся тем, что концентрация указанной кальциево-натриевой соли этилендиаминтетрауксусной кислоты (ЭДТА) составляет от примерно 0,1 до примерно 1,0 мг/мл.
11. Композиция по п.10, отличающаяся тем, что концентрация указанной кальциево-натриевой соли этилендиаминтетрауксусной кислоты (ЭДТА) составляет примерно 0,4 мг/мл.
12. Композиция по п.8, отличающаяся тем, что концентрация указанного гидрохлорида глицина составляет от примерно 0,5 до примерно 1,0 мг/мл.
13. Композиция по п.12, отличающаяся тем, что концентрация указанного гидрохлорида глицина составляет примерно 0,3 мг/мл.
14. Композиция по п.8, отличающаяся тем, что концентрация указанного бромида метилналтрексона составляет примерно 20 мг/мл, концентрация указанной кальциево-натриевой соли этилендиаминтетрауксусной кислоты (ЭДТА) составляет примерно 0,4 мг/мл, концентрация указанного гидрохлорида глицина составляет примерно 0,3 мг/мл, и pH указанного раствора составляет от примерно 2,6 до примерно 5,0.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83557406P | 2006-08-04 | 2006-08-04 | |
| US60/835,574 | 2006-08-04 | ||
| PCT/US2007/017430 WO2008019115A2 (en) | 2006-08-04 | 2007-08-03 | Formulations for parenteral delivery of compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008138266A true RU2008138266A (ru) | 2010-03-27 |
| RU2539387C2 RU2539387C2 (ru) | 2015-01-20 |
Family
ID=39033508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008138266/15A RU2539387C2 (ru) | 2006-08-04 | 2007-08-03 | Составы для парентеральной доставки соединений и их применение |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US20080070975A1 (ru) |
| EP (1) | EP2046388B1 (ru) |
| JP (1) | JP5356231B2 (ru) |
| KR (1) | KR20090040248A (ru) |
| CN (2) | CN101405031B (ru) |
| AR (1) | AR063471A1 (ru) |
| AU (1) | AU2007281984B8 (ru) |
| BR (1) | BRPI0708965B8 (ru) |
| CA (1) | CA2646901C (ru) |
| EC (1) | ECSP088752A (ru) |
| ES (1) | ES2655863T3 (ru) |
| GT (1) | GT200800185A (ru) |
| HN (1) | HN2008001464A (ru) |
| IL (2) | IL194182A (ru) |
| MX (1) | MX2008011993A (ru) |
| NO (1) | NO343701B1 (ru) |
| NZ (1) | NZ597260A (ru) |
| PE (1) | PE20080741A1 (ru) |
| PH (1) | PH12013500801A1 (ru) |
| PL (1) | PL2046388T3 (ru) |
| RU (1) | RU2539387C2 (ru) |
| SG (1) | SG174030A1 (ru) |
| TW (1) | TWI489984B (ru) |
| WO (1) | WO2008019115A2 (ru) |
| ZA (1) | ZA200808203B (ru) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
| US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| CN104383542B (zh) | 2003-04-08 | 2017-09-26 | 普罗热尼奇制药公司 | 包含甲基纳曲酮的药物配方 |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| TW200815451A (en) * | 2006-08-04 | 2008-04-01 | Wyeth Corp | 6-carboxy-normorphinan derivatives, synthesis and uses thereof |
| TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
| WO2008121352A2 (en) * | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof |
| DK2139890T3 (da) * | 2007-03-29 | 2014-08-25 | Wyeth Llc | Perifere opioidreceptor-antagonister og anvendelser deraf |
| PL2137191T3 (pl) | 2007-03-29 | 2016-12-30 | Antagoniści obwodowego receptora opioidowego i ich zastosowania | |
| WO2009099410A1 (en) * | 2008-02-06 | 2009-08-13 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r)-8-keto-methylnaltrexone |
| KR101581480B1 (ko) | 2008-02-06 | 2015-12-30 | 프로제닉스 파머슈티컬스, 인코포레이티드 | (ｒ),(ｒ)-2,2'-비스-메틸날트렉손의 제조법 및 용도 |
| EP2278966B1 (en) | 2008-03-21 | 2019-10-09 | The University of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| AU2013203119B2 (en) * | 2008-09-30 | 2015-12-03 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
| AU2016201221B2 (en) * | 2008-09-30 | 2017-08-10 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| MX344786B (es) * | 2009-07-28 | 2017-01-06 | Shire Human Genetic Therapies | Composiciones y metodos para tratar enfermedad de gaucher. |
| NZ703564A (en) | 2010-03-11 | 2016-08-26 | Wyeth Llc | Oral formulations and lipophilic salts of methylnaltrexone |
| SI2616064T1 (sl) | 2010-10-21 | 2019-12-31 | Rtu Pharmaceuticals Llc | Pripravki ketorolaka, pripravljeni za uporabo |
| CN102525911B (zh) * | 2012-03-20 | 2013-09-18 | 南京臣功制药股份有限公司 | 一种溴甲纳曲酮注射液及其制备方法 |
| CN103239452A (zh) * | 2013-01-25 | 2013-08-14 | 辽宁亿灵科创生物医药科技有限公司 | 一种溴甲基纳曲酮药物组合物 |
| CA2902343C (en) | 2013-03-14 | 2022-08-02 | Becton Dickinson France S.A.S. | Injectable morphine formulations |
| PT2968729T (pt) | 2013-03-14 | 2018-11-06 | Fresenius Kabi Deutschland Gmbh | Sistema de acondicionamento para fármacos sensíveis ao oxigénio |
| US20160128951A1 (en) * | 2013-07-29 | 2016-05-12 | Aizant Drug Research Solutions Pvt Ltd | Pharmaceutical compositions of fingolimod |
| JP6686013B2 (ja) | 2014-10-17 | 2020-04-22 | サリックス ファーマスーティカルズ，インコーポレーテッド | 腫瘍の進行を減弱させるためのメチルナルトレキソンの使用 |
| CN105769755A (zh) * | 2014-12-23 | 2016-07-20 | 北大方正集团有限公司 | 一种溴甲纳曲酮注射液及其制备方法 |
| US10695402B2 (en) * | 2017-03-16 | 2020-06-30 | University Of Rochester | Erythropoietin for gastrointestinal dysfunction |
| EP4360651A3 (en) | 2017-08-24 | 2024-07-17 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| WO2020012248A1 (en) | 2018-07-13 | 2020-01-16 | Alkermes Pharma Ireland Limited | Novel naphthylenyl compounds for long-acting injectable compositions and related methods |
| US10807995B2 (en) | 2018-07-13 | 2020-10-20 | Alkermes Pharma Ireland Limited | Thienothiophene compounds for long-acting injectable compositions and related methods |
| CN110960486B (zh) * | 2018-09-29 | 2022-05-13 | 北京凯因科技股份有限公司 | 一种溴甲纳曲酮注射液组合物 |
| WO2020094634A1 (en) | 2018-11-05 | 2020-05-14 | Alkermes Pharma Ireland Limited | Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods |
| TWI878456B (zh) | 2020-02-18 | 2025-04-01 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1組成物及其用途 |
| CN111303093A (zh) * | 2020-02-21 | 2020-06-19 | 重庆医药高等专科学校 | 一种溴甲纳曲酮杂质的制备方法 |
| US12514939B2 (en) | 2024-02-14 | 2026-01-06 | Alpha-9 Oncology, Inc. | Stable radiopharmaceutical compositions and uses thereof |
| CN120241599A (zh) * | 2025-05-12 | 2025-07-04 | 北京化药科创医药科技发展有限公司 | 一种耐受终端灭菌的溴甲纳曲酮注射液及其制备方法 |
Family Cites Families (293)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1420015B1 (de) | 1959-10-16 | 1971-08-26 | Boehringer Sohn Ingelheim | 2'-Hydroxy-5,9-dimethyl-6,7-benzomorphane |
| GB1202148A (en) | 1968-03-06 | 1970-08-12 | Sankyo Co | Pharmaceutical compositions |
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3714159A (en) | 1971-03-30 | 1973-01-30 | Janssen Pharmaceutica Nv | 2,2-diaryl-4-(4'-aryl-4'-hydroxy-piper-idino)-butyramides |
| US3884916A (en) | 1971-03-30 | 1975-05-20 | Janssen Pharmaceutica Nv | 2,2-Diaryl-4-(4-aryl-4-hydroxy-piperidino)-butyramides |
| US4326074A (en) | 1972-09-22 | 1982-04-20 | William H. Rorer, Inc. | Amidinoureas |
| US4025652A (en) | 1975-03-31 | 1977-05-24 | William H. Rorer, Inc. | Amidinoureas |
| US3937801A (en) | 1973-07-10 | 1976-02-10 | American Home Products Corporation | Reducing the incidence of gastrointestinal side effects during the treatment of inflammatory conditions with antiinflammatory drugs |
| US4060635A (en) | 1975-03-31 | 1977-11-29 | William H. Rorer, Inc. | Amidinoureas for treating diarrhea |
| US4203920A (en) | 1975-03-31 | 1980-05-20 | William H. Rorer, Inc. | Amidinoureas |
| US4066654A (en) | 1975-04-16 | 1978-01-03 | G. D. Searle & Co. | 1-triarylalkyl-4-phenyl-4-piperidine carboxylic acids and derivatives |
| US4072686A (en) | 1975-04-16 | 1978-02-07 | G. D. Searle & Co. | 1-(3,3,3-Triarylalkyl)-4-phenyl-piperidinealkanols |
| US3996214A (en) | 1976-02-23 | 1976-12-07 | G. D. Searle & Co. | 5-(1,1-Diphenyl-4-(cyclic amino) but-2-trans-en-1-yl)-2-alkyl-1,3,4-oxadiazoles and intermediates thereto |
| US4013668A (en) | 1976-03-10 | 1977-03-22 | G. D. Searle & Co. | 5-(1,1-diphenyl-3-(5- or 6-hydroxy-2-azabicyclo(2.2.2)oct-2-yl)propyl)-2-alkyl-1,3,4-oxadiazoles and related compounds |
| US4012393A (en) | 1976-03-22 | 1977-03-15 | G. D. Searle & Co. | 2-[5-(CYCLIC AMINO) ETHYL-10,11-DIHYDRO-5H-dibenzo[a,d]-cyclohepten-5- yl]-5 |
| US4115400A (en) | 1976-05-27 | 1978-09-19 | Eli Lilly And Company | 1-Azoniabicyclo[3.1.0]hexanes |
| GB1593191A (en) | 1977-03-23 | 1981-07-15 | Reckitt & Colmann Prod Ltd | Derivatives of morphine |
| US4125531A (en) | 1977-04-18 | 1978-11-14 | G. D. Searle & Co. | 2-Substituted-1-azabicyclo[2.2.2]octanes |
| US4069223A (en) | 1977-05-02 | 1978-01-17 | G. D. Searle & Co. | 4-Aminomethyl-1-(3,3,3-triarylpropyl)-4-arylpiperidine and derivatives thereof |
| US4116963A (en) | 1977-05-23 | 1978-09-26 | G.D. Searle & Co. | 3,3,3-triarylalkyl-4-phenylalkyl-4-hydroxy piperidines and related compounds |
| US4194045A (en) | 1977-12-27 | 1980-03-18 | G. D. Searle & Co. | 1-(3,3-Diaryl-3-oxadiazolalkyl)-4-phenyl-4-piperidinomethanols and related compounds |
| IT1096665B (it) | 1978-06-14 | 1985-08-26 | Tecnofarmaci Spa | Composizione farmaceutica per la terapia di stati di frigidita' ed impotenza |
| US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
| JPS5535031A (en) | 1978-09-04 | 1980-03-11 | Shin Etsu Chem Co Ltd | Enteric coating composition |
| US4311833A (en) | 1979-03-06 | 1982-01-19 | Daicel Chemical Industries Ltd. | Process for preparing ethylcarboxymethylcellulose |
| US4277605A (en) | 1980-03-07 | 1981-07-07 | Bristol-Myers Company | Chemical compounds |
| US4322426A (en) | 1980-04-28 | 1982-03-30 | E. I. Du Pont De Nemours And Company | 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4466968A (en) | 1980-11-24 | 1984-08-21 | Dermall, Ltd. | Method for prophylaxis or treatment of emesis and nausea |
| US4427676A (en) | 1980-12-19 | 1984-01-24 | John Wyeth & Brother Ltd. | Thiomorpholine derivatives |
| US4377568A (en) | 1981-08-12 | 1983-03-22 | Merck Sharp & Dohme (I.A.) Corp. | Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same |
| DK150008C (da) | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
| US4987136A (en) | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
| US4870084A (en) | 1982-03-16 | 1989-09-26 | Pfizer Inc. | Bicyclic benzo fused pyran compounds used for nausea treatment and prevention |
| WO1983003197A1 (en) | 1982-03-16 | 1983-09-29 | Univ Rockefeller | Method for controlling gastrointestinal dysmotility |
| US4430327A (en) | 1982-05-18 | 1984-02-07 | Eli Lilly And Company | Method for treating pregnant females for pain and anxiety |
| US4457907A (en) | 1982-08-05 | 1984-07-03 | Clear Lake Development Group | Composition and method for protecting a therapeutic drug |
| US4533739A (en) | 1982-10-12 | 1985-08-06 | G. D. Searle & Co. | 2-[(Aminophenyl and amidophenyl)amino]-1-azacycloalkanes having antidiarrheal activity |
| US4518433A (en) | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| JPS601128A (ja) | 1983-06-15 | 1985-01-07 | Shionogi & Co Ltd | 作用持続型セフアクロル製剤 |
| US4462839A (en) | 1983-06-16 | 1984-07-31 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
| US4556552A (en) | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US4689332A (en) | 1984-04-09 | 1987-08-25 | Research Corporation | Growth regulation and related applications of opioid antagonists |
| US5266574A (en) | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
| US4666716A (en) | 1984-09-04 | 1987-05-19 | Richardson-Vicks Inc. | Antidiarrheal compositions and use thereof |
| JPS6229515A (ja) | 1985-07-30 | 1987-02-07 | Shinjiro Tsuji | 硬カプセル剤のフイルムコ−テイング方法 |
| JPH0676314B2 (ja) | 1985-09-30 | 1994-09-28 | 花王株式会社 | 坐剤基剤及び坐剤 |
| US4824853A (en) | 1985-10-11 | 1989-04-25 | Janssen Pharmaceutica N.V. | α,α-diaryl-4-aryl-4-hydroxy-1-piperidinebutanamide, N-oxides and method of treating diarrhea |
| US4806556A (en) | 1985-12-12 | 1989-02-21 | Regents Of The University Of Minnesota | Gut-selective opiates |
| US4730048A (en) | 1985-12-12 | 1988-03-08 | Regents Of The University Of Minnesota | Gut-selective opiates |
| EP0306575B1 (en) | 1987-09-10 | 1992-07-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
| US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
| US4719215A (en) | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
| CA1297218C (en) | 1986-03-14 | 1992-03-10 | Edward David Weil | Thermally stable diphosphonate-type flame retardant additive for plastics |
| DE3609073C2 (de) | 1986-03-18 | 1995-08-10 | Hans J Prof Dr Rer Nat Schmitt | Meßeinrichtung zur nichtinvasiven Feststellung peripherer Abfluß- und Durchflußstörungen in menschlichen Extremitäten |
| US4990521A (en) | 1986-07-03 | 1991-02-05 | Janssen Pharmaceutica | 4-(aroylamino)piperidine-butanimide derivatives |
| DE3777658D1 (de) | 1986-08-28 | 1992-04-23 | Enzacor Pty Ltd | Tierwachstumserreger. |
| US5597564A (en) | 1986-08-28 | 1997-01-28 | Enzacor Properties Limited | Method of administering a microgranular preparation to the intestinal region of animals |
| US4888346A (en) | 1986-10-07 | 1989-12-19 | Bernard Bihari | Method for the treatment of persons infected with HTLV-III (AIDS) virus |
| US4765978A (en) | 1986-12-16 | 1988-08-23 | Schering Corporation | Novel vaginal suppository |
| FR2609632B1 (fr) | 1987-01-21 | 1991-03-29 | Shelly Marc | Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage |
| NL8700842A (ru) | 1987-04-10 | 1988-11-01 | Duphar Int Res | |
| US4891379A (en) | 1987-04-16 | 1990-01-02 | Kabushiki Kaisha Kobe Seikosho | Piperidine opioid antagonists |
| IL83086A (en) | 1987-07-06 | 1991-03-10 | Teva Pharma | Stable,injectable solutions of vincristine salts |
| US4857833A (en) | 1987-08-27 | 1989-08-15 | Teradyne, Inc. | Diagnosis of faults on circuit board |
| CA1315689C (en) | 1987-09-03 | 1993-04-06 | Leon I. Goldberg | Quarternary derivatives of noroxymorphone which relieve nausea and emesis |
| DE3744053A1 (de) | 1987-12-21 | 1989-07-13 | Schering Ag | Fungizides mittel mit synergistischer wirkung |
| US4912114A (en) | 1988-03-18 | 1990-03-27 | Sandoz Ltd. | Morphinan derivatives |
| EP0350221B1 (en) | 1988-06-30 | 1996-04-17 | Astra Aktiebolag | Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same |
| JPH0653683B2 (ja) | 1988-07-14 | 1994-07-20 | ザ ロックフェラー ユニバーシティ | 慢性痛あるいは慢性咳を治療する経口用組成物 |
| EP0352361A1 (en) | 1988-07-29 | 1990-01-31 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| US4999342A (en) | 1988-08-16 | 1991-03-12 | Ortho Pharmaceutical Corporation | Long lasting contraceptive suppository composition and methods of use |
| US4863928A (en) | 1989-01-04 | 1989-09-05 | Baker Cummins Pharmaceuticals, Inc. | Method of treatment for arthritic and inflammatory diseases |
| US5102887A (en) | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
| US5116868A (en) | 1989-05-03 | 1992-05-26 | The Johns Hopkins University | Effective ophthalmic irrigation solution |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US4965269A (en) | 1989-12-20 | 1990-10-23 | Ab Hassle | Therapeutically active chloro substituted benzimidazoles |
| US5236947A (en) | 1990-02-28 | 1993-08-17 | Jouveinal S.A. | Propanamines, their pharmacological properties and their application as an antidiarrheal |
| JPH0813748B2 (ja) | 1990-04-23 | 1996-02-14 | 帝國製薬株式会社 | 大腸崩壊性ポリペプチド系経口製剤 |
| ES2097208T3 (es) | 1990-05-11 | 1997-04-01 | Pfizer | Composiciones y procedimientos terapeuticos y sinergicos. |
| US5780012A (en) | 1990-06-21 | 1998-07-14 | Huland; Edith | Method for reducing lung afflictions by inhalation of cytokine solutions |
| JP3160862B2 (ja) | 1990-11-15 | 2001-04-25 | 雪印乳業株式会社 | 骨強化食品、飼料及び医薬 |
| JPH04230625A (ja) | 1990-12-27 | 1992-08-19 | Standard Chem & Pharmaceut Corp Ltd | 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法 |
| EP0573565B1 (en) | 1991-02-25 | 2000-07-19 | Trustees Of Boston University | Opiate receptor antagonist modulates hyperkinetic movement disorder |
| US5159081A (en) | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
| US5250542A (en) | 1991-03-29 | 1993-10-05 | Eli Lilly And Company | Peripherally selective piperidine carboxylate opioid antagonists |
| US5270328A (en) | 1991-03-29 | 1993-12-14 | Eli Lilly And Company | Peripherally selective piperidine opioid antagonists |
| CA2064373C (en) | 1991-03-29 | 2005-08-23 | Buddy Eugene Cantrell | Piperidine derivatives |
| US5220017A (en) | 1991-04-10 | 1993-06-15 | Merck & Co., Inc. | Cholecystokinin antagonists |
| JPH06508371A (ja) | 1991-06-21 | 1994-09-22 | ユニバーシティー オブ シンシナティ | 経口投与できる治療用タンパク質及びその製法 |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5614219A (en) | 1991-12-05 | 1997-03-25 | Alfatec-Pharma Gmbh | Oral administration form for peptide pharmaceutical substances, in particular insulin |
| US5256154A (en) | 1992-01-31 | 1993-10-26 | Sterling Winthrop, Inc. | Pre-filled plastic syringes and containers and method of terminal sterilization thereof |
| JPH05213763A (ja) | 1992-02-10 | 1993-08-24 | Sanwa Kagaku Kenkyusho Co Ltd | 易吸収活性化カルシウム製剤 |
| NL9220019A (nl) | 1992-04-10 | 1994-04-05 | Vnii Med Polimerov | Farmaceutische samenstelling. |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| USRE36547E (en) | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
| US5580876A (en) | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| US5472943A (en) | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
| US5512578A (en) | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
| WO1994008599A1 (en) | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
| GB9221707D0 (en) * | 1992-10-15 | 1992-12-02 | Smithkline Beecham Plc | Pharmaceutical composition |
| DK1975181T3 (da) | 1992-10-28 | 2011-06-06 | Genentech Inc | Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister |
| ATE143803T1 (de) | 1992-12-22 | 1996-10-15 | Univ Cincinnati | Orale verabreichung von immunologischen aktiven biomolekülen und anderen therapeutischen proteinen |
| DE4303214A1 (de) | 1993-02-04 | 1994-08-11 | Wolfgang Marks | Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone |
| US5585348A (en) | 1993-02-10 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia |
| US5656290A (en) | 1993-02-26 | 1997-08-12 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
| US5391372A (en) | 1993-06-28 | 1995-02-21 | Campbell; Elizabeth | Methods of treating colic and founder in horses |
| CA2143864C (en) | 1993-07-23 | 2006-01-24 | Hiroshi Nagase | Morphinan derivatives and pharmaceutical use thereof |
| US5358970A (en) * | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| GB2281205A (en) | 1993-08-24 | 1995-03-01 | Euro Celtique Sa | Oral opioid analgesic |
| SE9303744D0 (sv) | 1993-11-12 | 1993-11-12 | Astra Ab | Pharmaceutical emulsion |
| US5434171A (en) | 1993-12-08 | 1995-07-18 | Eli Lilly And Company | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
| US6190691B1 (en) | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
| WO1995030774A1 (en) | 1994-05-05 | 1995-11-16 | Beckman Instruments, Inc. | Oligonucleotide repeat arrays |
| IT1269826B (it) | 1994-05-24 | 1997-04-15 | Paolo Minoia | Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate |
| US5536507A (en) | 1994-06-24 | 1996-07-16 | Bristol-Myers Squibb Company | Colonic drug delivery system |
| US5866154A (en) * | 1994-10-07 | 1999-02-02 | The Dupont Merck Pharmaceutical Company | Stabilized naloxone formulations |
| US5614222A (en) | 1994-10-25 | 1997-03-25 | Kaplan; Milton R. | Stable aqueous drug suspensions and methods for preparation thereof |
| US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| US5578725A (en) | 1995-01-30 | 1996-11-26 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
| ES2094694B1 (es) | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. |
| US6096763A (en) | 1995-02-23 | 2000-08-01 | Merck & Co., Inc. | α1a adrenergic receptor antagonists |
| US6025154A (en) | 1995-06-06 | 2000-02-15 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein chemokine receptor HDGNR10 |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5821219A (en) | 1995-08-11 | 1998-10-13 | Oregon Health Sciences University | Opioid antagonists and methods of their use |
| GB9517001D0 (en) | 1995-08-18 | 1995-10-18 | Denny William | Enediyne compounds |
| US5804595A (en) | 1995-12-05 | 1998-09-08 | Regents Of The University Of Minnesota | Kappa opioid receptor agonists |
| DK0780372T3 (da) | 1995-12-21 | 2002-03-11 | Syngenta Participations Ag | 3-Amino-2-mercaptobenzoesyrederivater samt fremgangsmåder til deres fremstilling |
| EP0977558B1 (en) | 1996-02-15 | 2003-10-01 | Janssen Pharmaceutica N.V. | Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors |
| DK0914097T3 (da) | 1996-03-12 | 2002-04-29 | Alza Corp | Sammensætning og doseringsform omfattende opioid antagonist |
| US6136780A (en) | 1996-03-29 | 2000-10-24 | The Penn State Research Foundation | Control of cancer growth through the interaction of [Met5 ]-enkephalin and the zeta (ζ) receptor |
| US20040024006A1 (en) | 1996-05-06 | 2004-02-05 | Simon David Lew | Opioid pharmaceutical compositions |
| JP3648864B2 (ja) | 1996-08-28 | 2005-05-18 | 三菱自動車工業株式会社 | 希薄燃焼内燃機関 |
| DE19651551C2 (de) | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
| US20010036469A1 (en) | 1997-01-13 | 2001-11-01 | Gooberman Lance L. | Opiate antagonist implant and process for preparation therefor |
| DE59800046D1 (de) | 1997-02-14 | 1999-12-23 | Goedecke Ag | Stabilisierung von naloxonhydrochlorid |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| GB9801231D0 (en) | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
| HU9701081D0 (en) | 1997-06-23 | 1997-08-28 | Gene Research Lab Inc N | Pharmaceutical composition of antitumoral activity |
| US6525038B1 (en) | 1997-06-24 | 2003-02-25 | Werner Kreutz | Synergistic compositions for the selective control of tumor tissue |
| US6353004B1 (en) | 1997-07-14 | 2002-03-05 | Adolor Coporation | Peripherally acting anti-pruritic opiates |
| US6096764A (en) | 1997-08-21 | 2000-08-01 | Eli Lilly And Company | Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration |
| US6099853A (en) | 1997-09-04 | 2000-08-08 | Protein Express | Vaginal suppository vaccine for urogenital infections |
| US6559158B1 (en) | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
| US20030158220A1 (en) | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
| US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
| AU2003204844B2 (en) | 1997-11-03 | 2007-06-07 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
| US6274591B1 (en) | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
| ATE210983T1 (de) | 1997-11-03 | 2002-01-15 | Stada Arzneimittel Ag | Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum |
| US6777534B1 (en) | 1997-12-09 | 2004-08-17 | Children's Medical Center Corporation | Peptide antagonists of vascular endothelial growth factor |
| CA2314893C (en) | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
| EP0930334A1 (en) | 1998-01-16 | 1999-07-21 | Quest International B.V. | Polysaccharide conjugate capable of binding cellulose |
| AU3596599A (en) | 1998-01-26 | 1999-08-09 | Unilever Plc | Method for producing antibody fragments |
| GB9802251D0 (en) | 1998-02-03 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
| EP1068870B1 (en) | 1998-04-03 | 2006-06-07 | Ajinomoto Co., Inc. | Antitumor agents |
| DE19818802A1 (de) | 1998-04-27 | 1999-10-28 | Dresden Arzneimittel | Stabile Mitoxantron-Lösungen |
| US6359111B1 (en) | 1998-05-28 | 2002-03-19 | Neorx Corporation | Opioid receptor targeting |
| HN1999000149A (es) | 1998-09-09 | 2000-01-12 | Pfizer Prod Inc | Derivados de 4,4-biarilpiperidina |
| US20010010919A1 (en) | 1998-10-13 | 2001-08-02 | David K. Grandy | Opioid antagonists and methods of their use |
| EP1141711A1 (en) | 1999-01-05 | 2001-10-10 | Unilever Plc | Binding of antibody fragments to solid supports |
| DE60013767T3 (de) | 1999-01-19 | 2009-07-09 | Unilever N.V. | Verfahren zur herstellung von antikörperfragmenten |
| CA2293008A1 (en) | 1999-01-28 | 2000-07-28 | Hong Qi | Premixed alatrofloxacin injectable compositions |
| NZ513356A (en) | 1999-02-05 | 2004-01-30 | Univ Leiden | Method of modulating metabolite biosynthesis in recombinant cells using an AP2-domain transcription factor that is involved in the response of a plant cell to a jasmonate |
| US6194382B1 (en) | 1999-03-03 | 2001-02-27 | Albert Einstein College Of Medicine Of Yeshiva University | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists |
| JP4049477B2 (ja) | 1999-03-23 | 2008-02-20 | 大鵬薬品工業株式会社 | 副作用軽減剤 |
| WO2000065057A1 (en) | 1999-04-22 | 2000-11-02 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins |
| US7129265B2 (en) | 1999-04-23 | 2006-10-31 | Mason R Preston | Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy |
| US6171620B1 (en) | 1999-04-27 | 2001-01-09 | Health Research, Inc. | Method of enhancing the efficacy of anti-tumor agents |
| WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
| US20020068712A1 (en) | 1999-07-23 | 2002-06-06 | Troy Stevens | Use of decreasing levels of functional transient receptor potential gene product |
| US20030105121A1 (en) | 1999-07-27 | 2003-06-05 | Bernard Bihari | Method of preventing lipodystrophy syndrome or reversing a pre-existing syndrome in HIV-infected patients being treated with antiretroviral agents |
| IL147920A0 (en) | 1999-08-02 | 2002-08-14 | Keygene Nv | Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants |
| EP1206264A2 (en) | 1999-08-25 | 2002-05-22 | Barrett R. Cooper | Compositions and methods for treating opiate intolerance |
| ATE279186T1 (de) | 1999-08-31 | 2004-10-15 | Gruenenthal Gmbh | Retardierte darreichungsform enthaltend tramadolsaccharinat |
| CA2385990A1 (en) * | 1999-09-29 | 2001-04-05 | The Procter & Gamble Company | Compositions having improved stability |
| US6451806B2 (en) | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
| EP1225897B1 (en) | 1999-11-01 | 2004-09-08 | RHODES, John | Composition for treatment of constipation and irritable bowel syndrome |
| DE69927688T2 (de) | 1999-11-04 | 2006-07-06 | Institut Gustave Roussy | Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs |
| DK1244448T3 (da) | 1999-11-29 | 2009-08-17 | Adolor Corp | Nye metoder til behandling og forebyggelse af ileus |
| AU4136901A (en) | 1999-11-29 | 2001-06-18 | Adolor Corporation | Novel methods for the treatment and prevention of dizziness and pruritus |
| AU784541B2 (en) | 1999-11-29 | 2006-04-27 | Adolor Corporation | Novel methods and compositions involving opioids and antagonists thereof |
| US6469030B2 (en) | 1999-11-29 | 2002-10-22 | Adolor Corporation | Methods for the treatment and prevention of ileus |
| US6384044B1 (en) | 1999-11-29 | 2002-05-07 | Bernard Bihari | Method of treating cancer of the prostate |
| US6911455B2 (en) | 1999-12-22 | 2005-06-28 | Smithkline Beecham Corporation | Methods for preparing pharmaceutical formulations |
| US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
| US20010046968A1 (en) | 2000-03-23 | 2001-11-29 | Zagon Ian S. | Opioid growth factor modulates angiogenesis |
| US6967075B2 (en) | 2000-04-07 | 2005-11-22 | Schering Corporation | HCV replicase complexes |
| CA2408106A1 (en) | 2000-05-05 | 2001-11-15 | Pain Therapeutics, Inc. | Opioid antagonist compositions and dosage forms |
| CA2410371C (en) | 2000-06-22 | 2015-11-17 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
| EP1175905A1 (en) | 2000-07-24 | 2002-01-30 | Societe Des Produits Nestle S.A. | Nutritional Composition |
| FI116089B (sv) | 2000-07-27 | 2005-09-15 | Johan Tore Karlstroem | Anordning och förfaranden vid reglar |
| JP4265911B2 (ja) | 2000-07-28 | 2009-05-20 | エフ．ホフマン−ラ ロシュ アーゲー | 新規医薬組成物 |
| NZ507152A (en) | 2000-09-27 | 2001-06-29 | Hiltive Pty Ltd | Wall cladding assembly with cladding having recesses along opposite sides to engage with flanges of support members |
| WO2002060870A2 (en) | 2000-11-17 | 2002-08-08 | Adolor Corporation | Delta agonist analgesics |
| CA2364294C (en) | 2000-12-04 | 2013-04-02 | Primagen B.V. | Testing endosymbiont cellular organelles and compounds identifiable therewith |
| WO2002047716A2 (en) | 2000-12-13 | 2002-06-20 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
| UA73619C2 (en) | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
| KR100405161B1 (ko) | 2000-12-14 | 2003-11-12 | 신풍제약주식회사 | 록소프로펜 함유 근육주사제 조성물 |
| GB0100115D0 (en) | 2001-01-04 | 2001-02-14 | Alchemia Pty Ltd | Delivery systems |
| US6693125B2 (en) | 2001-01-24 | 2004-02-17 | Combinatorx Incorporated | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
| MXPA03008623A (es) | 2001-03-23 | 2004-05-21 | Shire Biochem Inc | Combinacion farmaceutica para el tratamiento del cancer. |
| US20040242523A1 (en) | 2003-03-06 | 2004-12-02 | Ana-Farber Cancer Institue And The Univiersity Of Chicago | Chemo-inducible cancer gene therapy |
| WO2002080987A1 (en) | 2001-04-09 | 2002-10-17 | Progenics Pharmaceuticals, Inc. | Anti-cd19 immunotoxins |
| BR0209198A (pt) | 2001-04-26 | 2004-06-08 | Control Delivery Sys Inc | Métodos de sìntese de compostos contendo fenol |
| ATE446751T1 (de) | 2001-06-05 | 2009-11-15 | Univ Chicago | Verwendung von methylnaltrexon zur behandlung von immunsuppression |
| CA2452382A1 (en) | 2001-07-10 | 2003-01-23 | Corixa Corporation | Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| EP1432429A4 (en) | 2001-08-31 | 2005-09-21 | Univ Louisiana State | ANGIOGENIC INHIBITION AND DESTRUCTION OF ANGIOGENIC VACUUM WITH EXTRACTS OF NONI JUICE (MORINDA CITRIFOLIA) |
| LT1436012T (lt) | 2001-10-18 | 2018-04-10 | Nektar Therapeutics | Opioidų antagonistų polimerų konjugatai |
| US20030144312A1 (en) | 2001-10-30 | 2003-07-31 | Schoenhard Grant L. | Inhibitors of ABC drug transporters in multidrug resistant cancer cells |
| WO2003037365A1 (en) | 2001-11-01 | 2003-05-08 | The Johns Hopkins University | Methods and compositions for treating vascular leak using hepatocyte growth factor |
| JP2005511693A (ja) | 2001-11-29 | 2005-04-28 | シェーリング コーポレイション | 回転異性体の薬学的に活性な塩の量が増加した組成物の調製のためのプロセス |
| EP1458710A4 (en) | 2001-12-21 | 2005-04-20 | Merck & Co Inc | Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
| US20050011468A1 (en) | 2002-02-04 | 2005-01-20 | Jonathan Moss | Use of methylnaltrexone in treating gastrointestinal dysfunction in equines |
| WO2004014291A2 (en) | 2002-02-04 | 2004-02-19 | Jonathan Moss | Use of methylnaltrexone in treating gastrointestinal dysfunction in equines |
| US7074825B2 (en) | 2002-03-07 | 2006-07-11 | Huanbiao Mo | Composition and method for treating cancer |
| EP1482912B1 (en) | 2002-03-14 | 2011-05-25 | Euro-Celtique S.A. | Naltrexone hydrochloride compositions |
| US20050176685A1 (en) | 2002-04-05 | 2005-08-11 | Daifotis Anastasia G. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| US20030191147A1 (en) | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
| US7355081B2 (en) | 2002-04-17 | 2008-04-08 | The University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
| AU2003273176A1 (en) | 2002-05-17 | 2003-12-12 | Board Of Regents, The University Of Texas System | Beta-2-glycoprotein 1 is an inhibitor of angiogenesis |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| US6986901B2 (en) | 2002-07-15 | 2006-01-17 | Warner-Lambert Company Llc | Gastrointestinal compositions |
| US20040010997A1 (en) | 2002-07-17 | 2004-01-22 | Oren Close | Guides to align masonry walls defining apertures, and methods of use |
| US7160913B2 (en) | 2002-09-13 | 2007-01-09 | Thomas Jefferson University | Methods and kit for treating Parkinson's disease |
| US7691374B2 (en) | 2002-10-23 | 2010-04-06 | Health Research, Inc. | Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody |
| DE60329520D1 (de) | 2002-11-08 | 2009-11-12 | Mallinckrodt Inc | Verfahren zur herstellung von quaternäre n-alkyl morphinan alkaloid salzen |
| JP2004183371A (ja) | 2002-12-04 | 2004-07-02 | Inax Corp | ユニットバスの補強構造 |
| AU2003296954A1 (en) | 2002-12-13 | 2004-07-09 | The Regents Of The University Of California | Analgesic combination comprising nalbuphine |
| WO2004054569A1 (en) | 2002-12-16 | 2004-07-01 | Council Of Scientific And Industrial Research | Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings |
| DE602004016127D1 (de) | 2003-03-07 | 2008-10-09 | Lilly Co Eli | Antagonisten der opioidrezeptoren |
| CN104383542B (zh) * | 2003-04-08 | 2017-09-26 | 普罗热尼奇制药公司 | 包含甲基纳曲酮的药物配方 |
| WO2004091622A1 (en) | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
| MXPA05010821A (es) | 2003-04-08 | 2006-03-30 | Progenics Pharm Inc | Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico. |
| CA2522708C (en) | 2003-04-29 | 2013-05-28 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| US6992193B2 (en) | 2003-06-10 | 2006-01-31 | Adolor Corporation | Sulfonylamino phenylacetamide derivatives and methods of their use |
| EP3342420A1 (en) | 2003-06-13 | 2018-07-04 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7494979B2 (en) | 2003-06-13 | 2009-02-24 | Ironwood Pharmaceuticals, Inc. | Method for treating congestive heart failure and other disorders |
| AU2003903387A0 (en) | 2003-07-02 | 2003-07-17 | Sirtex Medical Limited | Combination therapy for treatment of neoplasia |
| JP2007509722A (ja) | 2003-10-29 | 2007-04-19 | アレズ フィジオニックス リミテッド | 超音波流体の流動中心線を決定するための方法および装置 |
| SE0303135D0 (sv) | 2003-11-25 | 2003-11-25 | Lipocore Holding Ab | Controlled food effect composition |
| US8946262B2 (en) | 2003-12-04 | 2015-02-03 | Adolor Corporation | Methods of preventing and treating gastrointestinal dysfunction |
| US6984403B2 (en) | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
| AU2004303425C1 (en) | 2003-12-19 | 2010-02-18 | Schering Corporation | Pharmaceutical compositions |
| EP1701703B1 (en) | 2003-12-31 | 2011-03-09 | Bend Research, Inc. | Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers and stabilizing polymers |
| JP2005213763A (ja) | 2004-01-27 | 2005-08-11 | Yasushi Namihana | ドア開閉補助装置 |
| US20070082044A1 (en) | 2004-03-10 | 2007-04-12 | Trustees Of Tufts College | Synergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene |
| TW200533339A (en) | 2004-03-16 | 2005-10-16 | Bristol Myers Squibb Co | Therapeutic synergy of anti-cancer compounds |
| US6946556B1 (en) | 2004-05-21 | 2005-09-20 | Acura Pharmaceuticals, Inc. | Preparation of opioid analgesics by a one-pot process |
| US7094775B2 (en) | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
| US7388008B2 (en) | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
| US20060063792A1 (en) | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
| AU2005286662B2 (en) | 2004-09-23 | 2011-10-06 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| ES2392645T3 (es) | 2004-09-30 | 2012-12-12 | Becton,Dickinson And Company | Método para reducir o eliminar residuos en una recipiente médico de vidrio y recipiente hecho de acuerdo con el mismo |
| US20060177380A1 (en) | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
| EP1845989A1 (en) | 2005-01-20 | 2007-10-24 | Progenics Pharmaceuticals, Inc. | Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| CN101171010B (zh) | 2005-03-07 | 2014-09-17 | 芝加哥大学 | 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途 |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| US20080194611A1 (en) | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
| CA2609985A1 (en) | 2005-06-03 | 2007-05-10 | The University Of Chicago | Modulation of cell barrier dysfunction |
| AU2006255274A1 (en) | 2005-06-03 | 2006-12-14 | The University Of Chicago | Modulation of microbial pathogen-host cell interactions |
| WO2006135650A1 (en) | 2005-06-09 | 2006-12-21 | Mallinckrodt Inc. | Method for separation and purification of naltrexone by preparative chromatography |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| WO2007025383A1 (en) | 2005-08-30 | 2007-03-08 | Queen's University At Kingston | Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptoi agonists using an ultralow dose of an alpha-2 receptor antagonist |
| PL116330U1 (en) | 2005-10-31 | 2007-04-02 | Alza Corp | Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation |
| US20070259939A1 (en) | 2006-05-04 | 2007-11-08 | Accelerated Technologies | Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
| CA2671197A1 (en) | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophobic abuse deterrent delivery system |
| TW200815451A (en) | 2006-08-04 | 2008-04-01 | Wyeth Corp | 6-carboxy-normorphinan derivatives, synthesis and uses thereof |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| WO2008021394A2 (en) | 2006-08-15 | 2008-02-21 | Theraquest Biosciences, Llc | Pharmaceutical formulations of cannabinoids and method of use |
| TW200817048A (en) | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
| CA2670342A1 (en) | 2006-11-22 | 2008-06-12 | Progenics Pharmaceuticals, Inc. | N-oxides of 4,5-epoxy-morphinanium analogs |
| MX2009005462A (es) | 2006-11-22 | 2009-08-28 | Progenics Pharm Inc | Analogos de 7,8-saturados-4,5-epoxi-morfinano. |
| AU2007323718A1 (en) | 2006-11-22 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Processes for synthesizing quaternary 4,5-epoxy-morphinan analogs and isolating their N-stereoisomers |
| TW200843802A (en) | 2007-02-09 | 2008-11-16 | Drugtech Corp | Compositions for improving gastrointestinal nutrient and drug absorption |
| WO2008121352A2 (en) | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof |
| PL2137191T3 (pl) | 2007-03-29 | 2016-12-30 | Antagoniści obwodowego receptora opioidowego i ich zastosowania | |
| DK2139890T3 (da) | 2007-03-29 | 2014-08-25 | Wyeth Llc | Perifere opioidreceptor-antagonister og anvendelser deraf |
| KR101581480B1 (ko) | 2008-02-06 | 2015-12-30 | 프로제닉스 파머슈티컬스, 인코포레이티드 | (ｒ),(ｒ)-2,2'-비스-메틸날트렉손의 제조법 및 용도 |
| EA201001643A1 (ru) | 2008-05-07 | 2011-06-30 | Нектар Терапеутикс | Пероральное введение периферически действующих опиоидных антагонистов |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| CN101845047B (zh) | 2009-12-31 | 2011-12-07 | 南京臣功制药有限公司 | 一种溴甲基纳曲酮的制备方法 |
| NZ703564A (en) | 2010-03-11 | 2016-08-26 | Wyeth Llc | Oral formulations and lipophilic salts of methylnaltrexone |
| CA2859203C (en) | 2011-12-19 | 2020-08-25 | Salix Pharmaceuticals, Ltd. | Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone |
| US10485798B2 (en) | 2012-08-22 | 2019-11-26 | Aptapharma Inc. | Methylnaltrexone nasal formulations, methods of making, and use thereof |
| BR112021022194A2 (pt) | 2019-05-07 | 2021-12-28 | Bausch Health Ireland Ltd | Formulações líquidas para dosagem oral de metilnaltrexona |
-
2007
- 2007-07-30 TW TW096127790A patent/TWI489984B/zh active
- 2007-08-03 WO PCT/US2007/017430 patent/WO2008019115A2/en not_active Ceased
- 2007-08-03 PL PL07836531T patent/PL2046388T3/pl unknown
- 2007-08-03 US US11/890,034 patent/US20080070975A1/en not_active Abandoned
- 2007-08-03 MX MX2008011993A patent/MX2008011993A/es active IP Right Grant
- 2007-08-03 RU RU2008138266/15A patent/RU2539387C2/ru active
- 2007-08-03 JP JP2009522896A patent/JP5356231B2/ja active Active
- 2007-08-03 AR ARP070103440A patent/AR063471A1/es unknown
- 2007-08-03 EP EP07836531.9A patent/EP2046388B1/en active Active
- 2007-08-03 SG SG2011055670A patent/SG174030A1/en unknown
- 2007-08-03 PE PE2007001019A patent/PE20080741A1/es not_active Application Discontinuation
- 2007-08-03 BR BRPI0708965A patent/BRPI0708965B8/pt active IP Right Grant
- 2007-08-03 IL IL194182A patent/IL194182A/en active IP Right Grant
- 2007-08-03 AU AU2007281984A patent/AU2007281984B8/en active Active
- 2007-08-03 KR KR1020087023010A patent/KR20090040248A/ko not_active Ceased
- 2007-08-03 ES ES07836531.9T patent/ES2655863T3/es active Active
- 2007-08-03 CN CN2007800097236A patent/CN101405031B/zh active Active
- 2007-08-03 NZ NZ597260A patent/NZ597260A/xx unknown
- 2007-08-03 CN CN2012103079336A patent/CN102846613A/zh active Pending
- 2007-08-03 CA CA2646901A patent/CA2646901C/en active Active
-
2008
- 2008-09-18 GT GT200800185A patent/GT200800185A/es unknown
- 2008-09-18 NO NO20083973A patent/NO343701B1/no unknown
- 2008-09-19 EC EC2008008752A patent/ECSP088752A/es unknown
- 2008-09-22 HN HN2008001464A patent/HN2008001464A/es unknown
- 2008-09-25 ZA ZA200808203A patent/ZA200808203B/xx unknown
-
2010
- 2010-03-17 US US12/726,113 patent/US20100249169A1/en not_active Abandoned
-
2012
- 2012-09-05 IL IL221795A patent/IL221795B/en active IP Right Grant
-
2013
- 2013-04-24 PH PH12013500801A patent/PH12013500801A1/en unknown
- 2013-12-13 US US14/105,805 patent/US20150025100A1/en not_active Abandoned
-
2016
- 2016-05-19 US US15/158,967 patent/US20160338946A1/en active Granted
-
2019
- 2019-07-17 US US16/514,722 patent/US20200179270A1/en not_active Abandoned
-
2021
- 2021-06-24 US US17/357,023 patent/US20220023200A1/en not_active Abandoned
-
2023
- 2023-09-11 US US18/244,446 patent/US12303592B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008138266A (ru) | Составы для парентерального введения лекарств и их применения | |
| HRP20150037T1 (hr) | Farmaceutske formulacije koje sadrže metilnaltrekson | |
| BRPI0517916B8 (pt) | comprimido compreendendo carbonato de sevelamer e cloreto de sódio, e, uso de um comprimido | |
| JP2009545603A5 (ru) | ||
| EA200400777A1 (ru) | Фармацевтические композиции соединения платины | |
| NZ595526A (en) | Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant | |
| TW200509923A (en) | A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid | |
| JP2010529999A5 (ru) | ||
| EA200400154A1 (ru) | Новые лекарственные формы замещенного бензимидазола и способ их применения | |
| MEP39808A (en) | Highly concentrated stable meloxicam solutions | |
| JP2006516272A5 (ru) | ||
| RU2013150659A (ru) | Пероральное введение кальцитонина | |
| RU2004124063A (ru) | Сигарета и сигаретный фильтр | |
| RU2007111484A (ru) | Составы, содержащие пиперациллин, тазобактам и аминокарбоновую кислоту в растворителе лактата натрия | |
| RU2014114512A (ru) | Водные композиции, содержащие арбекацин | |
| MXPA06007510A (es) | Composiciones de farmaco y formas de dosis novedosas de topiramato. | |
| RU2005105691A (ru) | Пероральное введение кальцитонина | |
| JP2005531528A5 (ru) | ||
| CL2004000858A1 (es) | Peptidos que comprende una region acida, una lipofilica o aromatica y una basica, que participan en transporte inverso de colesterol, composicion farmaceutica que los contienen, util para el tratamiento o prevencion de hipercolesterolemia y/o aterosc | |
| RU2011111117A (ru) | Лечение аутоиммунных заболеваний | |
| EA200600377A1 (ru) | Новая композиция | |
| ATE538782T1 (de) | Modifizierte aminosaeure 5-cnac zur hemmung der thrombozytenaggregation | |
| CA2362772A1 (en) | Pharmaceutical formulation for intraveous or intramuscular octreotide administration | |
| US3708574A (en) | Pharmaceutical compositions providing potassium chloride in aqueous solution | |
| JP2002284673A (ja) | 生理学的に許容可能な水溶液の調製法およびこの方法により得られた溶液 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant |